title: Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
abstract: We present the case of a 70-year-old man diagnosed with multiple myeloma in 2008, who after four therapy lines initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally). The patient was treated with pomalidomide for almost 2 years achieving a complete remission after 12 cycles. Complete remission was maintained for 9 months. This case illustrates the potential of pomalidomide plus low-dose dexamethasone to overcome multiple myeloma refractoriness inducing a quick and very prolonged remission.
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Angelo
authors.initials: A
authors.lastname: Palmas
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Piras
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Uras
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Rosanna
authors.initials: R
authors.lastname: Asproni
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Murineddu
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Monne
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Roberta
authors.initials: R
authors.lastname: Stradoni
authors.affiliation: Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Local Health Trust of Nuoro, Italy.
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Latte
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D019233:Retreatment; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D013792:Thalidomide; C467566:pomalidomide
keywords: complete response; drug resistance; immunomodulatory drug; pomalidomide; refractory multiple myeloma; relapsed multiple myeloma